Results 1 to 10 of about 216,694 (240)
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
New England Journal of Medicine, 2008 Emmanuelle Waubant +2 more
exaly +3 more sources
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
CNS Drugs, 2022 There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing–remitting multiple sclerosis (RRMS).
L. Freeman +4 more
semanticscholar +1 more source
JAMA Neurology, 2021 Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary markedly between Denmark and Sweden. The difference in the association of these national strategies with clinical outcomes is unknown.
T. Spelman +9 more
semanticscholar +1 more source
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
JAMA Neurology, 2023 Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a
I. Roos +35 more
semanticscholar +1 more source
Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis [PDF]
Frontiers in Neurology, 2015 Fatigue, cognitive, and affective disorders are relevant symptoms in multiple sclerosis (MS). The treatment with Natalizumab has a positive effect on physical disabilities in patients with relapsing-remitting MS (RRMS). Some studies describe improvements in cognition and fatigue over 1 year of treatment.
Kunkel, Annett +5 more
openaire +3 more sources
JAMA Neurology, 2023 This randomized clinical trial evaluates matching efficacy, safety, and immunogenicity between biosimilar natalizumab and reference natalizumab in patients with relapsing-remitting multiple sclerosis.
B. Hemmer +7 more
semanticscholar +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023 Background Differences in pain between subtypes of multiple sclerosis are understudied. Objective To compare the prevalence of pain, and the association between pain and: (a) pain interference and (b) social participation in people with relapsing ...
Dhruv Jain +9 more
doaj +1 more source
Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients. [PDF]
PLoS ONE, 2012 Interferon-β is a first-line therapy used to prevent relapses in relapsing-remitting multiple sclerosis. The clinical benefit of interferon-β in relapsing-remitting multiple sclerosis is attributed to its immunomodulatory effects on inflammatory ...
Nicolas Molnarfi +4 more
doaj +1 more source
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis
Frontiers in Immunology, 2023 ObjectivesRecent studies supported coagulation involvement in multiple sclerosis, an inflammatory-demyelinating and degenerative disease of the central nervous system. The main objectives of this observational study were to identify the most specific pro-
Tatiana Koudriavtseva +21 more
doaj +1 more source
Role of Diet and Supplementation with Omega-3 Polyunsaturated Fatty Acids for Managing Chronic Fatigue in Patients with Relapsing-Remitting Multiple Sclerosis [PDF]
Journal of Biomedical & Clinical Research, 2022 Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS) with unclear and multifactorial etiology, variable clinical symptoms with different severity, and treatment with limited efficacy.
Nicholas Shepherd +5 more
doaj +3 more sources